A new way for a new world

August 14, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

Ref: Scrip Code: 532296

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Unaudited Financial Results (Standalone and Consolidated) for the First Quarter ended 30th June, 2025

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the First Quarter ended 30th June, 2025.

The said Board Meeting commenced at 02:00 p.m. and ended at 04:11 p.m.

The copy of the said results is enclosed herewith.

They are also being made available on the website of the Company at www.glenmarkpharma.com

You are requested to take the same on records.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Encl: As above

glenmark
A new way for a new world

Glenmark Pharmaceuticals Limited
Statement of Unaudited financial results for the quarter ended 30 June 2025
(All amounts in million of Indian Rupees, unless otherwise stated)

	Particulars	Standalone			
		Quarter ended 30/06/2025 (Unaudited)	Quarter ended 31/03/2025 (Refer note 6)	Quarter ended 30/06/2024 (Unaudited)	Year ended 31/03/2025 (Audited)
I	Revenue from operations				
	(a) Net sales	21,788.96	19,099.36	22,968.75	90,105.42
	(b) Other operating income	2,160.32	995.57	326.62	2,158.67
	Total revenue from operations	23,949.28	20,094.93	23,295.37	92,264.09
II	Other income	693.35	884.52	556.48	3,563.66
III	Total income (I + II)	24,642.63	20,979.45	23,851.85	95,827.75
IV	Expenses				
	(a) Cost of materials consumed	6,772.40	6,960.13	6,481.09	27,814.47
	(b) Purchases of stock-in-trade	993.25	914.82	889.85	3,732.07
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(584.10)	(13.78)	569.24	444.76
	(d) Employee benefits expense	4,084.43	3,827.03	3,844.03	16,034.98
	(e) Finance costs	154.58	131.27	153.49	487.33
	(f) Depreciation, amortisation and impairment expense	576.39	555.29	530.87	2,186.29
	(g) Other expenses	5,401.71	5,001.48	5,200.14	21,796.01
	Total expenses (IV)	17,398.66	17,376.24	17,668.71	72,495.91
V	Profit/(loss) before exceptional items and tax (III - IV)	7,243.97	3,603.21	6,183.14	23,331.84
VI	Exceptional items (gain)/ loss (Refer note 5)	3,232.32	1,791.66	-	1,791.66
VII	Profit/(loss) before tax (V - VI)	4,011.65	1,811.55	6,183.14	21,540.18
VIII	Tax expense :				
	Current tax	701.72	(256.21)	1,079.84	3,160.87
	Deferred tax	7.67	590.16	565.99	2,275.81
IX	Profit/(loss) after tax for the period / year (VII - VIII)	3,302.26	1,477.60	4,537.31	16,103.50
X	Profit/(loss) for the period / year attributable to:				
	- Non-controlling interests	-	-	-	-
	- Owners of the Company	3,302.26	1,477.60	4,537.31	16,103.50
XI	Other comprehensive income / (loss)				
	A (i) Items that will not be reclassified to profit or loss	(8.20)	(46.13)	(12.52)	(99.39)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	2.86	16.12	4.37	34.73
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other comprehensive income/(loss) for the period/ year	(5.34)	(30.01)	(8.15)	(64.66)
XII	Total comprehensive income for the period/ year (IX + XI)	3,296.92	1,447.59	4,529.16	16,038.84
XIII	Total comprehensive income attributable to:				
	- Non-controlling interests	-	-	-	-
	- Owners of the Company	3,296.92	1,447.59	4,529.16	16,038.84
XIV	Paid up Equity Share Capital, Equity Shares of Re. 1/- each	282.20	282.19	282.19	282.19
XV	Other equity (other than revaluation reserve)				2,44,757.37
XVI	Earning per share (EPS)				
	(not annualised except for the year ended 31 March)				
	Basic (in Rupees)	11.70	5.24	16.08	57.07
	Diluted (in Rupees)	11.70	5.24	16.08	57.07

SURESH SURANA & ASSOCIATES LLP Chartered Accountants MUMBAI

GLENMARK PHARMACEUTICALS LTD. MUMBAI

Glenmark Pharmaceuticals Limited
Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India
T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No. L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

glenmark
A new way for a new world

Glenmark Pharmaceuticals Limited
Statement of Unaudited financial results for the quarter ended 30 June 2025
(All amounts in million of Indian Rupees, unless otherwise stated)

	Particulars	Consolidated			
		Quarter ended 30/06/2025 (Unaudited)	Quarter ended 31/03/2025 (Refer note 6)	Quarter ended 30/06/2024 (Unaudited)	Year ended 31/03/2025 (Audited)
I	Revenue from operations				
	(a) Net sales	30,593.33	32,201.32	32,233.02	1,31,458.36
	(b) Other operating income	2,051.07	360.74	208.84	1,759.04
	Total revenue from operations	32,644.40	32,562.06	32,441.86	1,33,217.40
II	Other income	264.42	116.85	314.92	1,137.22
III	Total income (I + II)	32,908.82	32,678.91	32,756.78	1,34,354.62
IV	Expenses				
	(a) Cost of materials consumed	7,324.68	7,947.76	6,857.74	30,012.72
	(b) Purchases of stock-in-trade	5,813.41	3,447.44	3,600.26	15,660.03
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,982.33)	(505.72)	642.82	(2,139.33)
	(d) Employee benefits expense	7,627.54	7,365.70	7,104.40	30,220.61
	(e) Finance costs	582.26	667.12	395.82	2,070.65
	(f) Depreciation, amortisation and impairment expense	1,299.26	1,252.05	1,177.89	4,860.10
	(g) Other expenses	9,055.90	8,696.63	8,354.51	35,949.56
	Total expenses (IV)	28,720.72	28,870.98	28,133.44	1,16,634.34
V	Profit/(loss) before exceptional items and tax (III - IV)	4,188.10	3,807.93	4,623.34	17,720.28
VI	Exceptional items (gain)/ loss (Refer note 5)	3,232.32	3,728.19	-	3,728.19
VII	Profit/(loss) before tax (V - VI)	955.78	79.74	4,623.34	13,992.09
VIII	Tax expense :				
	Current tax	1,093.11	(35.04)	1,468.82	3,823.41
	Deferred tax	(607.06)	70.94	(247.86)	(302.74)
IX	Profit/(loss) after tax for the period / year (VII - VIII)	469.73	43.84	3,402.38	10,471.42
X	Profit/(loss) for the period / year attributable to:				
	- Non-controlling interests	1.02	(2.66)	(0.29)	0.45
	- Owners of the Company	468.71	46.50	3,402.67	10,470.97
XI	Other comprehensive income / (loss)				
	A (i) Items that will not be reclassified to profit or loss	8.64	(61.88)	(7.01)	(119.76)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(1.83)	19.54	2.79	38.36
	B (i) Items that will be reclassified to profit or loss	1,017.60	2,609.56	60.50	867.40
	(ii) Income tax relating to items that will be reclassified to profit or loss	(11.29)	8.57	(1.36)	(144.02)
	Total other comprehensive income/(loss) for the period/ year	1,013.12	2,575.79	54.92	641.98
XII	Total comprehensive income for the period/ year (IX + XI)	1,482.85	2,619.63	3,457.30	11,113.40
XIII	Total comprehensive income attributable to:				
	- Non-controlling interests	0.87	(2.83)	(0.26)	0.08
	- Owners of the Company	1,481.98	2,622.46	3,457.56	11,113.32
XIV	Paid up Equity Share Capital, Equity Shares of Re. 1/- each	282.20	282.19	282.19	282.19
XV	Other equity (other than revaluation reserve)				88,212.22
XVI	Earning per share (EPS)				
	(not annualised except for the year ended 31 March)				
	Basic (in Rupees)	1.66	0.16	12.06	37.11
	Diluted (in Rupees)	1.66	0.16	12.06	37.11

SURESH SURANA & ASSOCIATES LLP Chartered Accountants MUMBAI

GLENMARK PHARMACEUTICALS LTD. MUMBAI

Glenmark Pharmaceuticals Limited
Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India
T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No. L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Notes:

1. The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

2. The above results were reviewed by the Audit Committee at its meeting held on 13 August, 2025 and approved by the Board of Directors at their meetings held on 14 August, 2025. The results for the quarter ended 30 June, 2025 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.

3. The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.

4. As at 30 June, 2025, pursuant to Employee Stock Options Scheme 2016, 131,881 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.

5. Exceptional items:

   Standalone and Consolidated :
   30.06.2025
   The Company and its subsidiary were named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S. These relate to industry-wide allegations concerning price-fixing, market allocation, and related anticompetitive conduct. Plaintiffs include putative classes of direct purchasers, end-payers, and indirect purchasers of generic drugs, as well as numerous private, direct-action plaintiffs.
   Glenmark has agreed to enter into a settlement with the putative direct purchaser class, for a total of US$ 37.75 million. The settlement is subject to approval by the court overseeing the litigation.
   The settlement makes clear that Glenmark denies each and everyone of its allegation against it and the settlement is not on the basis of Glenmark having considered or admitted any liability or illegality.
   In view of the above the Company has made a provision for the estimated settlement amount of Rs. 3,232.32 (US$ 37.75 million)and charged the same to Profit and loss account as an exceptional item in the financial result for the quarter ended 30 June 2025.

SURESH SURANA & ASSOCIATES LLP Chartered Accountants MUMBAI

GLENMARK PHARMACEUTICALS LTD. MUMBAI

Standalone:
31.03.2025
The Company had earlier reported that the Company and its US subsidiary (Glenmark Pharmaceuticals Inc., USA) had arrived at a settlement with three Plaintiff Groups collectively representing all of the claims against the Company and Merck in relation to multiple antitrust and consumer protection lawsuits, including a class action, consolidated in the Eastern District of Virginia, U.S. (the "Court") for a total amount of US$ 87.5 million (US Dollar Eighty Seven Point Five million), payable over two financial years. Four End-Payor Plaintiffs, Humana Inc. (District of New Jersey), Centene Corporation, WellCare Health Plans, Inc., New York Quality Healthcare Corporation dba Fidelis Care, and Health Net, LLC (collectively "Centene") (District of New Jersey), Kaiser Foundation Health Plan, Inc. (Northern District of California), and United Healthcare Services, Inc. (District of Minnesota), opted out of the 2023 settlements. The Company and its US subsidiary (GPI) arrived at a settlement, in February 2025, with Humana, Centene, and Kaiser for a sum of US$ 7.0 million representing all of their claims against GPI and the Company. The settlement Agreement required the amount to be paid by the Company one month post obtaining all necessary approvals. The settlements made clear that it is a commercial settlements and not on the basis of the Company having conceded or admitted any liability, offence, wrongdoing or illegality.

In view of the above, the Company has charged the same to profit and loss account the settlement amount along with other associated legal cost for the case and others of Rs. 1,623.74 for the year ended 31 March 2025. Due to the non-recurring nature of the provision, the Company has classified this provision as an exceptional item in the financial statements for the quarter and year ended 31 March 2025.

IGI, the innovation arm of the Company underwent restructuring during the year. This was done to optimise operations in line with IGI's long-term vision. Accordingly, exceptional loss of Rs. 167.92 has been incurred for the year ended 31 March 2025 which comprises of restructuring costs, severance payments, and other one-time costs.

Consolidated:
31.03.2025
The Company had earlier reported that The Company and its US subsidiary (Glenmark Pharmaceuticals Inc., USA) had arrived at a settlement with Three Plaintiff Groups collectively representing all of the claims against the Company and Merck in relation to multiple antitrust and consumer protection lawsuits, including a class action, consolidated in the Eastern District of Virginia, U.S. (the "Court") for a total amount of US$ 87.5 million (US Dollar Eighty Seven Point Five million), payable over two financial years. Four End-Payor Plaintiffs, Humana Inc. (District of New Jersey), Centene Corporation, WellCare Health Plans, Inc., New York Quality Healthcare Corporation dba Fidelis Care, and Health Net, LLC (collectively "Centene") (District of New Jersey), Kaiser Foundation Health Plan, Inc. (Northern District of California), and United Healthcare Services, Inc. (District of Minnesota), opted out of the 2023 settlements. The Company and its US subsidiary (GPI) arrived at a settlement, in February 2025, with Humana, Centene, and Kaiser for a sum of US$ 7.0 million representing all of their claims against GPI

Suresh Surana & Associates LLP Chartered Accountants Mumbai

Glenmark Pharmaceuticals Ltd. Mumbai

and the Company. The settlement Agreement required the amount to be paid by the Company one month post obtaining all necessary approvals. The settlements made clear that it is a commercial settlements and not on the basis of the Company having conceded or admitted any liability, offence, wrongdoing or illegality.

In view of the above, the Company has charged the same to profit and loss account the settlement amount along with other associated legal cost for the case and others of Rs. 1,749.99 for the year ended 31 March 2025. Due to the non-recurring nature of the provision, the Company has classified this provision as an exceptional item in the financial statements for the quarter and year ended 31 March 2025.

IGI, the innovation arm of the Company underwent restructuring leading to closure of some development projects. Additionally, it was decided to shut-down IGI's manufacturing facility at Le-Chaux-De-Fonds in a phased manner. This led to a significant reduction in the facility's workforce and operations during the financial year.

To ensure continuity, it was decided to transfer CMC activities to a Contract Development and Manufacturing Organization (CDMO).

Accordingly, an exceptional loss of Rs. 1,978.20 was incurred during the year ended 31 March, 2025, which broadly comprises of Restructuring costs, One-time project write-offs, Inventory scrapping, People Costs (including Severance Payments), tech-transfer costs along-with other non-recurring costs.

6. The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter ended 31 December, 2024.

7. The list of subsidiaries as of 30 June 2025 is provided in Annexure A.

8. Diluted EPS has been computed considering the effect of conversion of ESOPs.

9. Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

For and on behalf of the Board of Directors

Glenn Saldanha
Chairman & Managing Director

Mumbai, 14 August 2025

GLENMARK PHARMACEUTICALS LTD. MUMBAI

SURESH SURANA & ASSOCIATES LLP Chartered Accountants MUMBAI

glenmark
A new way for a new world

Glenmark Pharmaceuticals Limited	
Annexure A	
List of entities included in the consolidated financial results for the quarter ended 30 June 2025	
Sr. No	**Name of Entities**
1	Glenmark Pharmaceuticals Europe Ltd., U.K.
2	Glenmark Pharmaceuticals S.R.O.
3	Glenmark Pharmaceuticals SK, S.R.O.
4	IGI Therapeutics SA (Formerly known as Ichnos Sciences SA)
5	Glenmark Holding S.A.
6	Glenmark Pharmaceuticals SP z.o.o.
7	Glenmark Pharmaceuticals Inc.
8	Glenmark Therapeutics Inc.
9	Glenmark Farmaceutica Ltda
10	Glenmark Generics S.A
11	Glenmark Pharmaceuticals Mexico, S.A. DE C.V.
12	Glenmark Pharmaceuticals Peru SAC
13	Glenmark Pharmaceuticals Colombia SAS, Colombia
14	Glenmark Uruguay S.A.
15	Glenmark Pharmaceuticals Venezuela, C.A
16	Glenmark Dominicana SRL
17	Glenmark Pharmaceuticals Egypt S.A.E.
18	Glenmark Pharmaceuticals FZE
19	Glenmark Impex L.L.C
20	Glenmark Philippines Inc.
21	Glenmark Pharmaceuticals (Nigeria) Ltd
22	Glenmark Pharmaceuticals Malaysia Sdn Bhd
23	Glenmark Pharmaceuticals (Australia) Pty Ltd
24	Glenmark South Africa (pty) Ltd
25	Glenmark Pharmaceuticals South Africa (pty) Ltd
26	Glenmark Pharmaceuticals (Thailand) Co. Ltd
27	Glenmark Pharmaceuticals B.V.
28	Glenmark Arzneimittel GmbH - Germany
29	Glenmark Pharmaceuticals Canada Inc.
30	Glenmark Pharmaceuticals Kenya Ltd
31	Glenmark Farmaceutica S.L.U. (Formerly known as Viso Farmaceutica S.L., Spain)
32	Glenmark Specialty SA
33	Glenmark Pharmaceuticals Distribution s.r.o.
34	Glenmark Pharmaceuticals Nordic AB
35	Glenmark Ukraine LLC
36	Glenmark-Pharmaceuticals Ecuador S.A.
37	Glenmark Pharmaceuticals Singapore Pte. Ltd.
38	Ichnos Glenmark Innovation Inc. (Formerly known as Ichnos Sciences Inc.)
39	Glenmark Healthcare Limited
40	Glenmark Farmaceutica SpA
41	Sintesy Pharma S.R.L
42	Glenmark Arzenimittel GmbH - Austria
43	Glenmark Consumer Care Limited (Incorporated on 23rd May 2025)
44	IGI Biotherapeutics SA (merged with IGI Therapeutics SA)

SURESH SURANA & ASSOCIATES LLP Chartered Accountants MUMBAI

GLENMARK PHARMACEUTICALS LTD. MUMBAI

Suresh Surana & Associates LLP
Chartered Accountants

Suresh Surana & Associates LLP

8th Floor, Bakhtawar
229, Nariman Point
Mumbai – 400 021, India

T + 91 (22) 2287 5770

emails@ss-associates.com www.ss-associates.com
LLP Identity No. AAB-7509

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

To
The Board of Directors
Glenmark Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Glenmark Pharmaceuticals Limited** ("the Company"), for the quarter ended 30 June 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Suresh Surana & Associates LLP
Chartered Accountants
Firm's Registration No.: 121750W/W100010

(Vinodkumar Varma)
Partner
Membership No. 105545
UDIN: 25105545BMNVOM1377

SURESH SURANA & ASSOCIATES LLP Chartered Accountants MUMBAI

Place: Mumbai
Date: 14 August 2025

Suresh Surana & Associates LLP
8th Floor, Bakhtawar
229, Nariman Point
Mumbai – 400 021, India
T + 91 (22) 2287 5770
emails@ss-associates.com www.ss-associates.com
LLP Identity No. AAB-7509

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

To the Board of Directors of Glenmark Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Glenmark Pharmaceuticals Limited** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 June 2025 ("the Statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Holding's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We did not review the interim financial results of the 43 subsidiaries included in the unaudited consolidated financial results, whose interim financial results, without giving effects to elimination of intra-group transaction reflect total revenues of Rs.23,849.87 million for the quarter ended 30 June 2025, total net loss after tax of Rs.1,059.75 million for the quarter ended 30 June 2025 and total comprehensive Income of Rs.125.05 million for the quarter ended 30 June 2025, as considered in the Statement. These interim financial results have been reviewed by the other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

SURESH SURANA & ASSOCIATES LLP
Chartered Accountants
MUMBAI

Further of the above 37 subsidiaries, located outside India, interim financial results have been prepared in accordance with International Financial Reporting Standards, and which have been reviewed by other auditors under International Standards on Review Engagement applicable in their respective countries. The Holding Company's management has converted the financial results of such subsidiaries from International Financial Reporting Standards to accounting principles generally accepted in India. We have reviewed these changes made by the Holding Company's management. Our conclusion, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based on the review reports of other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done by and the reports of the other auditors.

For Suresh Surana & Associates LLP
Chartered Accountants
Firm's Reg. No.: 121750W / W100010

Varma V.V

(Vinodkumar Varma)
Partner
Membership No. 105545

SURESH SURANA & ASSOCIATES LLP Chartered Accountants MUMBAI

UDIN: 25105545BMNVON7786

Place: Mumbai
Date: 14 August 2025

Annexure 1 Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Glenmark Pharmaceuticals Limited for the quarter ended 30 June 2025

List of subsidiaries included in the Statement.

1. Glenmark Pharmaceuticals Europe Ltd.
2. Glenmark Pharmaceuticals S.R.O.
3. Glenmark Pharmaceuticals SK. S.R.O.
4. IGI Therapeutics SA (formerly known as Ichnos Sciences SA)
5. Glenmark Holding SA
6. Glenmark Pharmaceuticals SP z.o.o.
7. Glenmark Pharmaceuticals Inc.
8. Glenmark Therapeutics Inc.
9. Glenmark Farmaceutica Ltda.
10. Glenmark Generics S.A
11. Glenmark Pharmaceuticals Mexico, S.A. DE C. V.
12. Glenmark Pharmaceuticals Peru SAC
13. Glenmark Pharmaceuticals Colombia SAS
14. Glenmark Uruguay S.A.
15. Glenmark Pharmaceuticals Venezuela, C.A
16. Glenmark Dominicana SRL
17. Glenmark Pharmaceuticals Egypt S.A.E.
18. Glenmark Pharmaceuticals FZE
19. Glenmark Impex L.L.C
20. Glenmark Philippines Inc.
21. Glenmark Pharmaceuticals (Nigeria) Ltd
22. Glenmark Pharmaceuticals Malaysia Sdn Bhd.
23. Glenmark Pharmaceuticals (Australia) Pty Ltd
24. Glenmark South Africa (Pty) Ltd
25. Glenmark Pharmaceuticals South Africa (Pty) Ltd
26. Glenmark Pharmaceuticals (Thailand) Co. Ltd
27. Glenmark Pharmaceuticals B.V.
28. Glenmark Arzneimittel Gmbh, Germany
29. Glenmark Pharmaceuticals Canada Inc.
30. Glenmark Pharmaceuticals Kenya Ltd.
31. Glenmark Farmaceutica S.L.U. (Formerly known as Viso Farmaceutica S.L.U., Spain)
32. Glenmark Specialty SA
33. Glenmark Pharmaceuticals Distribution s.r.o.
34. Glenmark Pharmaceuticals Nordic AB
35. Glenmark Ukraine LLC
36. Glenmark Pharmaceuticals Ecuador S.A.
37. Glenmark Pharmaceuticals Singapore Pte. Ltd.
38. Ichnos Glenmark Innovation Inc. (formerly known as Ichnos Sciences Inc.)
39. Sintesy Pharma S.R.L.
40. Glenmark Farmaceutica SPA
41. Glenmark Healthcare Limited
42. Glenmark Arzenimittel GmbH, Austria
43. Glenmark Consumer Care Limited (incorporated on 23 May 2025)
44. IGI Biotherapeutics SA (formerly known as Ichnos Sciences Biotherapeutics SA) (merged with IGI Therapeutics SA)

SURESH SURANA & ASSOCIATES LLP
Chartered Accountants
MUMBAI